Argen X SE News - ARGX

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts...

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART®...

argenx to Present at Upcoming Investor Conferences

February 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

February 22, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo...

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more...

argenx Highlights 2024 Strategic Priorities

Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for...

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to...

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod...

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Study did not meet primary or secondary endpointsFavorable safety and tolerability profile consistent with...

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Argen X SE (ARGX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ARGX News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at Upcoming Investor Conferences

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx Highlights 2024 Strategic Priorities

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

ARGX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Argen X SE (ARGX) News

Argen X SE (ARGX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ARGX News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at Upcoming Investor Conferences

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx Highlights 2024 Strategic Priorities

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

ARGX Discussion

Your Recent History